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BACKGROUND: Patients with chronic coronary artery disease or peripheral 
artery disease and history of heart failure (HF) are at high risk for major adverse 
cardiovascular events. We explored the effects of rivaroxaban with or without 
aspirin in these patients.
METHODS: The COMPASS trial (Cardiovascular Outcomes for People Using 
Anticoagulation Strategies) randomized 27 395 participants with chronic coronary 
artery disease or peripheral artery disease to rivaroxaban 2.5 mg twice daily 
plus aspirin 100 mg daily, rivaroxaban 5 mg twice daily alone, or aspirin 100 mg 
alone. Patients with New York Heart Association functional class III or IV HF or 
left ventricular ejection fraction (EF) <30% were excluded. The primary major 
adverse cardiovascular events outcome comprised cardiovascular death, stroke, or 
myocardial infarction, and the primary safety outcome was major bleeding using 
modified International Society of Thrombosis and Haemostasis criteria. Investigators 
recorded a history of HF and EF at baseline, if available. We examined the effects of 
rivaroxaban on major adverse cardiovascular events and major bleeding in patients 
with or without a history of HF and an EF <40% or ≥40% at baseline.
RESULTS: Of the 5902 participants (22%) with a history of HF, 4971 (84%) had EF 
recorded at baseline, and 12% had EF <40%. Rivaroxaban and aspirin had similar 
relative reduction in major adverse cardiovascular events compared with aspirin in 
participants with HF (5.5% versus 7.9%; hazard ratio [HR], 0.68; 95% CI, 0.53–
0.86) and those without HF (3.8% versus 4.7%; HR, 0.79; 95% CI, 0.68–0.93; P for 
interaction 0.28) but larger absolute risk reduction in those with HF (HF absolute risk 
reduction 2.4%, number needed to treat=42; no HF absolute risk reduction 1.0%, 
number needed to treat=103). The primary major adverse cardiovascular events 
outcome was not statistically different between those with EF <40% (HR, 0.88; 
95% CI, 0.55–1.42) and ≥40% (HR, 0.81; 95% CI, 0.67–0.98; P for interaction 
0.36). The excess hazard for major bleeding was not different in participants with HF 
(2.5% versus 1.8%; HR, 1.36; 95% CI, 0.88–2.09) than in those without HF (3.3% 
versus 1.9%; HR, 1.79; 95% CI, 1.45–2.21; P for interaction 0.26). There were no 
significant differences in the primary outcomes with rivaroxaban alone.
CONCLUSIONS: In patients with chronic coronary artery disease or peripheral 
artery disease and a history of mild or moderate HF, combination rivaroxaban and 
aspirin compared with aspirin alone produces similar relative but larger absolute 
benefits than in those without HF.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique 
identifier: NCT01776424.
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Most patients with heart failure (HF) have con-comitant coronary artery disease (CAD),1 which can lead to worsening HF through myo-
cardial ischemia or infarction and can also predispose 
to adverse cardiovascular events. Patients with CAD or 
peripheral artery disease (PAD) who also have HF have 
nearly a 2-fold higher risk of subsequent cardiovascu-
lar events than those without HF despite contemporary 
medical therapy that typically includes aspirin.
The COMMANDER HF trial (A Study to Assess the 
Effectiveness and Safety of Rivaroxaban in Reducing 
the Risk of Death, Myocardial Infarction, or Stroke in 
Participants with Heart Failure and Coronary Artery Dis-
ease Following an Episode of Decompensated Heart 
Failure) tested whether patients with chronic CAD, a 
reduced ejection fraction (EF; <40%), and a recent (<1 
month) acute hospitalization for HF would benefit from 
the addition of rivaroxaban 2.5 mg BID to contempo-
rary medical therapy.2 Rivaroxaban did not reduce the 
primary outcome, a composite of stroke, myocardial 
infarction (MI), or all-cause mortality. In contrast, the 
COMPASS trial (Cardiovascular Outcomes for People 
Using Anticoagulation Strategies) demonstrated that 
in patients with chronic CAD and PAD, the combina-
tion of rivaroxaban 2.5 mg twice daily and aspirin 100 
mg once daily reduced the relative risk of stroke, MI, 
or cardiovascular death (major adverse cardiovascular 
events [MACE]) by 24% compared with aspirin.3 Un-
like COMMANDER, COMPASS excluded patients with 
recently decompensated HF or severe HF as defined by 
baseline EF of ≤30% or New York Heart Association 
functional class III or IV HF. In the present report, we ex-
plore the effects of rivaroxaban with or without aspirin 
on MACE and bleeding in COMPASS patients with or 
without a history of HF and according to left ventricular 
EF recorded at baseline.
METHODS
COMPASS (ClinicalTrials.gov NCT01776424) is a multicenter, 
double-blind, randomized, placebo-controlled trial of 27 395 
stable patients with chronic CAD and PAD comparing rivar-
oxaban 2.5 mg twice daily plus aspirin 100 mg once daily or 
rivaroxaban 5 mg twice daily to aspirin 100 mg once daily 
(rivaroxaban arm).4 The primary outcome was a composite 
of cardiovascular death, stroke, or MI, and the main safety 
outcome was a modification of the International Society of 
Thrombosis and Haemostasis (ISTH) major bleeding criteria. 
The trial design and inclusion and exclusion criteria have 
been reported previously. This included methods for random-
ization to pantoprazole or placebo for patients who were 
not taking a proton pump inhibitor at baseline.4 Human 
subjects approval was obtained for each center, and writ-
ten informed consent was obtained from all participants. 
Patients with severe HF with known left ventricular EF <30% 
or New York Heart Association functional class III or IV symp-
toms and those requiring oral anticoagulation or dual-anti-
platelet therapy were excluded. A history of atrial fibrillation 
was not recorded at the time of randomization. A history of 
HF at randomization was determined by the clinical site and 
included both preserved and reduced EF. No further crite-
ria or documentation were required. Baseline left ventricular 
EF was recorded when available but was not an inclusion 
requirement for COMPASS.
The data that support the findings of this study are avail-
able from the corresponding author on reasonable request, 
although anonymized data and materials will be made pub-
licly available in the near future. As part of a preplanned 
subanalysis, we report the effects of randomized treat-
ments in patients with or without a history of or current HF 
at baseline and according to EF at baseline (<40%, ≥40%, 
or no EF data available) on the primary outcome of MACE, 
MACE plus HF hospitalization during the trial, mortality, and 
major bleeding.4 We defined HF with reduced EF (HFrEF) as 
Clinical Perspective
What Is New?
• The COMMANDER HF trial (A Study to Assess 
the Effectiveness and Safety of Rivaroxaban in 
Reducing the Risk of Death, Myocardial Infarc-
tion, or Stroke in Participants with Heart Failure 
and Coronary Artery Disease Following an Episode 
of Decompensated Heart Failure) demonstrated 
that in patients with coronary artery disease, low 
ejection fraction (≤40%), and recent heart failure 
exacerbation, low-dose rivaroxaban treatment did 
not improve major adverse cardiovascular events, 
although thrombotic outcomes were reduced.
• In participants in the COMPASS trial (Cardiovascular 
Outcomes for People Using Anticoagulation Strate-
gies) with a history of mild to moderate heart failure 
(exclusion criteria included left ventricular ejection 
fraction <30% and New York Heart Association 
functional class III and IV heart failure), combina-
tion rivaroxaban 2.5 mg BID and aspirin compared 
with aspirin alone demonstrated consistent relative 
risk reduction but higher absolute risk reduction for 
major adverse cardiovascular events and mortality 
compared with those without heart failure.
What Are the Clinical Implications?
• Patients with a history of mild to moderate heart 
failure and chronic atherosclerotic disease are a 
high-risk population, and the addition of low-dose 
rivaroxaban 2.5 mg BID to aspirin results in a similar 
relative but higher absolute risk reduction in major 
adverse cardiovascular events and mortality com-
pared with those without heart failure.
• In COMPASS trial patients with a decreased ejec-
tion fraction (≤40%), the higher cardiovascular 
mortality outnumbers the antithrombotic ben-
efits of low-dose rivaroxaban and is directionally 
consistent with the neutral findings in the COM-
MANDER HF trial.
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EF <40% and HF with preserved EF as EF ≥40%. Net clinical 
benefit was defined as the primary efficacy outcome plus 
severe bleeding (fatal bleeding or bleeding into a critical 
organ), as reported previously.3
Statistical Analysis
Analyses were conducted according to the intention-to-
treat principle. We compared baseline characteristics of 
patients with and without HF at baseline using Wilcoxon 
2-sample tests for continuous variables and Pearson χ2 tests 
for categorical variables. Survival analyses were based on 
the time to a first event. Patients could have >1 event, but 
we counted only the first event. We separately compared 
each of 2 rivaroxaban-based regimens with the aspirin-only 
control group using stratified log-rank tests. The stratum 
variable was treatment with proton pump inhibitor at base-
line: not randomized to proton pump inhibitor, random-
ized to active pantoprazole, or randomized to pantoprazole 
placebo. We estimated hazard ratios (HR) and correspond-
ing 95% CIs using Cox proportional hazards models strati-
fied by treatment with proton pump inhibitor at baseline. 
The assumption of the proportional hazards was verified 
using the plots of log of the negative log of survival func-
tion against the log of time. A 2-sided P value <0.05 was 
considered significant. There was no correction for multiple 
comparisons. All data were housed and analyzed at the 
Population Health Research Institute in Hamilton, Ontario, 
Canada, independently from the sponsor. Analyses were 
performed with SAS software for Linux, version 9.4 (SAS 
Institute Inc, Cary, NC).
RESULTS
Baseline characteristics of the trial population are 
shown in Table  1. Of the 27 395 patients enrolled in 
COMPASS, 5902 (22%) had a history of HF at base-
line. Left ventricular EF was available in 16 792 patients 
(61.3%), including 4971 of 5902 (84.2%) of those with 
HF. Patients with HF were younger, were more likely 
to be Eastern European, had a higher rate of current 
Table 1. Baseline Characteristics of Patients With or Without a History 
of Heart Failure at Baseline
No Heart Failure 
(N=21 493)
Heart Failure 
(N=5902) P Value
Age, y 69.0±7.5 65.5±9.0 <0.0001
Female sex 4653 (21.6) 1367 (23.2) 0.01
Body mass index, kg/m2 28.2±4.6 29.0±5.0 <0.0001
Systolic blood pressure, mm Hg 136±18 133±17 <0.0001
Heart rate, bpm 67±11 69±10 <0.0001
Total cholesterol, mg/dL 159±39 170±46 <0.0001
Tobacco use
  Never 6846 (31.9) 1911 (32.4) 0.44
  Former 10 533 (49.0) 2238 (37.9) <0.0001
  Current 4114 (19.1) 1753 (29.7) <0.0001
Hypertension 15 632 (72.7) 5000 (84.7) <0.0001
Diabetes mellitus 7915 (36.8) 2426 (41.1) <0.0001
Previous stroke 766 (3.6) 266 (4.5) 0.0008
Previous myocardial infarction 12 497 (58.1) 4531 (76.8) <0.0001
Left ventricular ejection fraction
  <40% 282 (1.3) 721 (12.2) <0.0001
  ≥40% 10 321 (48.0) 4250 (72.0) <0.0001
  Unknown 10 890 (50.7) 931 (15.8) <0.0001
NYHA categories
  Class I … 2130 (36.1) …
  Class II … 3765 (63.8) …
  Class III … 6 (0.1) …
  Class IV … 0 …
Coronary artery disease 19 110 (88.9) 5714 (96.8) <0.0001
Peripheral artery disease 6079 (28.3) 1391 (23.6) <0.0001
Peripheral artery bypass surgery 720 (3.3) 105 (1.8) <0.0001
Peripheral percutaneous 
transluminal angioplasty
1265 (5.9) 169 (2.9) <0.0001
Estimated GFR
  <30 mL·min−1·1.73 m−2 167 (0.8) 76 (1.3) 0.0002
  30 to <60 mL·min−1·1.73 
m−2
4593 (21.4) 1440 (24.4) <0.0001
  ≥60 mL·min−1·1.73 m−2 16 725 (77.8) 4386 (74.3) <0.0001
Race
  White 13 354 (62.1) 3673 (62.2) 0.89
  Black 201 (0.9) 61 (1.0) 0.49
  Asian 3479 (16.2) 790 (13.4) <0.0001
  Other 4459 (20.7) 1378 (23.3) <0.0001
Geographic region
  North America 3552 (16.5) 366 (6.2) <0.0001
  South America 4733 (22.0) 1411 (23.9) 0.002
  Western Europe, Israel, 
Australia, or South Africa
7724 (35.9) 831 (14.1) <0.0001
  Eastern Europe 2281 (10.6) 2542 (43.1) <0.0001
  Asia-Pacific 3203 (14.9) 752 (12.7) <0.0001
(Continued )
Medication
  ACE inhibitor or ARB 14 866 (69.2) 4652 (78.8) <0.0001
  Calcium-channel blocker 5854 (27.2) 1415 (24.0) <0.0001
  Diuretic agent 5427 (25.3) 2712 (46.0) <0.0001
  β-Blocker 14 382 (66.9) 4802 (81.4) <0.0001
  Lipid-lowering agent 19 203 (89.3) 5398 (91.5) <0.0001
  NSAID 1193 (5.6) 277 (4.7) 0.01
Values are mean±SD for continuous variables and frequency (%) for 
categorical variables. P value is from the Wilcoxon 2-sample test for continuous 
variables and Pearson χ2 test for categorical variables. ACE indicates 
angiotensin-converting enzyme; ARB, angiotensin receptor blocker; GFR, 
glomerular filtration rate; NSAID, nonsteroidal anti-inflammatory drug; and 
NYHA, New York Heart Association.
Table 1. Continued
No Heart Failure 
(N=21 493)
Heart Failure 
(N=5902) P Value
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smoking, and were more likely to have a history of MI 
(Table 1).  Patients with HF were also more often treated 
with an angiotensin-converting enzyme inhibitor or an-
giotensin receptor blocker, diuretic, β-blocker, and lipid-
lowering agent than patients without HF (Table 1).
HF and Outcomes
Patients with a history of HF had higher rates of the 
primary composite of cardiovascular mortality, MI, and 
stroke and of total mortality than those without HF 
(Figure  1). Rivaroxaban plus aspirin compared with 
aspirin alone reduced the relative risk of the primary 
composite MACE outcome by 32% in patients with 
HF compared with 21% in those without HF (Figure 1; 
P=0.28 for interaction). The absolute risk reduction 
(ARR) for patients with HF was 2.4% (number needed 
to treat [NNT]=42) versus 1.0% (NNT=103) for those 
without HF. Admissions for HF in patients with baseline 
HF were higher than for those without HF, although 
the rates were similar between those treated with riva-
roxaban with aspirin and aspirin alone (Table 2). Riva-
roxaban plus aspirin reduced the relative risk of death 
of any cause by 34% in those with HF (ARR, 2.1%; 
NNT=48) but had a smaller effect in those without 
HF (Table 2; P=0.05 for interaction). In patients with 
HF, stroke occurred in 82 patients (1.4%) compared 
with 260 (1.2%) of those without HF. Rivaroxaban 
with aspirin reduced the relative risk of stroke by 52% 
(HR, 0.48; 95% CI, 0.28–0.83) in patients with HF 
and reduced stroke by 38% in those without HF (HR, 
0.62; 95% CI, 0.45–0.84; P=0.43 for interaction). In 
patients with HF, MI occurred in 141 patients (2.4%) 
compared with 424 (2.0%) of those without HF. Riva-
roxaban with aspirin numerically reduced the relative 
risk of MI by 23% (HR, 0.77; 95% CI, 0.51–1.15) in 
patients with HF compared with 11% (HR, 0.89; 95% 
CI, 0.71–1.13; P=0.5 for interaction). Rivaroxaban 5 
mg BID alone compared with aspirin did not reduce 
the occurrence of the primary composite MACE out-
comes irrespective of whether patients had a history 
of HF (Table 2).
Major bleeding and individual bleeding components 
were similar between patients with and without HF 
(Table  2). Major bleeding was numerically lower but 
not statistically different for rivaroxaban plus aspirin in 
patients with or without HF (Table 2; P=0.26 for inter-
action). The net clinical benefit for rivaroxaban with as-
pirin was positive in patients with HF (ARR 2.4%, NNT 
42) and in those without HF (ARR, 0.8%; NNT=125), 
but these were not statistically heterogeneous (Ta-
ble 2). Major bleeding was increased with rivaroxaban 
alone (Table 2).
Left Ventricular EF and Outcomes
Patients with HF who had an available left ventricular EF 
(84% of all HF patients) predominantly had EFs ≥40% 
(n=4250; 72%), with fewer having EFs <40% (721; 
12%; Figure I in the online-only Data Supplement). The 
Figure 1. Kaplan–Meier cumulative hazard rates.  
A, Composite outcome of cardiovascular death, stroke, or myocardial infarction. B, Death from any cause. C, Major bleeding, by heart failure status at baseline 
and treatment with rivaroxaban plus aspirin or aspirin alone. Events were tabulated as time to first event. HF indicates heart failure.
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primary MACE event rates in patients with EF <40% 
were 53% higher than in those with EF >40% (Table 3). 
The primary MACE and safety outcomes were similar 
according to EF category (<40%, ≥40%, EF unknown; 
Table 3). Other outcomes were not statistically different 
by treatment group and baseline EF (Table 3). Cardiac 
arrest occurred in 0.9% of all patients with HF and was 
slightly higher in those with EF <40% than in those 
with EF ≥40% or EF unknown [1.4% versus 0.9% ver-
sus 0.4%, respectively). Cardiac arrest rates were simi-
lar for patients with EF <40% treated with rivaroxaban 
with aspirin (P=0.94 for interaction). Incident atrial 
fibrillation occurred in 1.6% of patients with HF dur-
ing the trial, with a higher incidence among those with 
EF <40% than among those with EF ≥40% and those 
with unknown EF (2.4% versus 1.6% versus 0.9%, 
 respectively). There was no evidence of a treatment in-
teraction with rivaroxaban plus aspirin by EF for major 
bleeding (P=0.47 for interaction; Table 3). There were 
no significant differences with rivaroxaban 5 mg BID 
treatment alone compared with aspirin for the primary 
MACE outcome if patients had a history of HF (Table 2) 
or by EF category (Table 3).
Comparison of the COMPASS and 
COMMANDER HF Results
In patients in COMPASS with HF and EF <40%, the com-
posite of all-cause death, MI, and stroke (the primary 
end point in the COMMANDER HF trial2) was 14.2% 
for aspirin and 12.7% for rivaroxaban plus aspirin, with 
a relative risk reduction of 13% (Table 4).
Table 2. Effect of Antithrombotic Therapies According to HF Status at Baseline
No. of First Events/Patients (%)
Rivaroxaban Plus Aspirin 
Versus Aspirin Alone
Rivaroxaban Alone Versus 
Aspirin Alone
Rivaroxaban 
Plus Aspirin 
(N=9152)
Rivaroxaban 
Alone 
(N=9117)
Aspirin Alone 
(N=9126) HR (95% CI)
P for 
Interaction HR (95% CI)
P for 
Interaction
Efficacy outcomes
  Cardiovascular death, stroke, or 
myocardial infarction
    0.28  0.20
   No HF 271/7189 (3.8) 324/7157 (4.5) 339/7147 (4.7) 0.79 (0.68–0.93)  0.95 (0.82–1.11)  
   HF 108/1963 (5.5) 124/1960 (6.3) 157/1979 (7.9) 0.68 (0.53–0.86)  0.80 (0.63–1.01)  
  Hospitalization for heart failure     0.05  0.30
   No HF 98/7189 (1.4) 81/7157 (1.1) 76/7147 (1.1) 1.29 (0.95–1.74)  1.06 (0.78–1.45)  
   HF 57/1963 (2.9) 57/1960 (2.9) 69/1979 (3.5) 0.82 (0.58–1.16)  0.83 (0.58–1.18)  
  Death of any cause     0.05  0.07
   No HF 227/7189 (3.2) 264/7157 (3.7) 249/7147 (3.5) 0.91 (0.76–1.09)  1.06 (0.89–1.26)  
   HF 86/1963 (4.4) 102/1960 (5.2) 129/1979 (6.5) 0.66 (0.50–0.86)  0.80 (0.61–1.03)  
Safety outcomes
  Major bleeding     0.26  0.81
   No HF 239/7189 (3.3) 199/7157 (2.8) 134/7147 (1.9) 1.79 (1.45–2.21)  1.49 (1.20–1.86)  
   HF 49/1963 (2.5) 56/1960 (2.9) 36/1979 (1.8) 1.36 (0.88–2.09)  1.59 (1.05–2.42)  
  Symptomatic bleeding into 
critical organ
    0.94  0.60
   No HF 56/7189 (0.8) 69/7157 (1.0) 41/7147 (0.6) 1.36 (0.91–2.03)  1.69 (1.15–2.48)  
   HF 17/1963 (0.9) 16/1960 (0.8) 12/1979 (0.6) 1.42 (0.68–2.97)  1.34 (0.64–2.84)  
  Intracranial bleeding     0.59  0.27
   No HF 19/7189 (0.3) 37/7157 (0.5) 18/7147 (0.3) 1.05 (0.55–2.00)  2.06 (1.17–3.61)  
   HF 9/1963 (0.5) 6/1960 (0.3) 6/1979 (0.3) 1.46 (0.52–4.11)  1.01 (0.33–3.14)  
Net clinical benefit outcome
  Cardiovascular death, stroke, 
myocardial infarction, fatal 
bleeding, or symptomatic 
bleeding into a critical organ
    0.15  0.14
   No HF 315/7189 (4.4) 370/7157 (5.2) 369/7147 (5.2) 0.85 (0.73–0.99)  1.00 (0.87–1.16)  
   HF 116/1963 (5.9) 134/1960 (6.8) 165/1979 (8.3) 0.69 (0.55–0.88)  0.82 (0.65–1.03)  
Percent (%) is the proportion of patients with an outcome. HRs (95% CI) are from the stratified Cox proportional hazards regression models fit in the respective 
subgroup. HF indicates heart failure; and HR, hazard ratio.
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DISCUSSION
In patients with chronic CAD and PAD with a history 
of HF at baseline, the combination of rivaroxaban and 
aspirin compared with aspirin alone produced similar 
relative risk reductions but larger ARRs in MACE and 
all-cause mortality compared with those who did not 
have HF at baseline. There was no excess in major or 
fatal bleeding in patients with HF. This translated into a 
numerically greater net clinical benefit for combination 
rivaroxaban and aspirin in patients with compared with 
those without HF. Rivaroxaban alone did not reduce the 
composite MACE outcome for those patients with or 
without HF, but it did increase major bleeding. Most 
patients with HF enrolled in COMPASS had preserved EF 
≥40% (88%), and there were no significant differences 
Table 3. Effect of Antithrombotic Therapies in Patients With a History of HF at Baseline According to EF Categories
No. of First Events/Patients (%)
Rivaroxaban Plus Aspirin 
Versus Aspirin Alone
Rivaroxaban Alone Versus 
Aspirin Alone
Rivaroxaban 
Plus Aspirin 
(N=1963)
Rivaroxaban 
Alone 
(N=9117)
Aspirin Alone 
(N=1979) HR (95% CI)
P for 
Interaction HR (95% CI)
P for 
Interaction
Efficacy outcomes
  Cardiovascular death, stroke, or 
myocardial infarction
    0.51  0.34
   HF and EF <40% 24/236 (10.2) 31/245 (12.7) 29/240 (12.1) 0.82 (0.47–1.40)  1.07 (0.65–1.78)  
   HF and EF ≥40% 69/1427 (4.8) 75/1405 (5.3) 98/1418 (6.9) 0.68 (0.50–0.93)  0.77 (0.57–1.04)  
   HF and EF unknown 15/300 (5.0) 18/310 (5.8) 30/321 (9.3) 0.53 (0.28–0.98)  0.64 (0.35–1.15)  
Hospitalization for heart failure     0.83  0.34
   HF and EF <40% 16/236 (6.8) 22/245 (9.0) 20/240 (8.3) 0.77 (0.40–1.48)  1.08 (0.59–1.98)  
   HF and EF ≥40% 37/1427 (2.6) 27/1405 (1.9) 42/1418 (3.0) 0.87 (0.56–1.35)  0.65 (0.40–1.05)  
   HF and EF unknown 4/300 (1.3) 8/310 (2.6) 7/321 (2.2) 0.56 (0.16–1.91)  1.15 (0.42–3.17)  
  Death of any cause     0.27  0.33
   HF and EF <40% 23/236 (9.7) 27/245 (11.0) 24/240 (10.0) 0.96 (0.54–1.71)  1.13 (0.65–1.96)  
   HF and EF ≥40% 50/1427 (3.5) 58/1405 (4.1) 77/1418 (5.4) 0.63 (0.44–0.90)  0.75 (0.53–1.06)  
   HF and EF unknown 13/300 (4.3) 17/310 (5.5) 28/321 (8.7) 0.49 (0.25–0.94)  0.65 (0.35–1.18)  
Safety outcomes
  Major bleeding     0.47  0.39
   HF and EF <40% 11/236 (4.7) 10/245 (4.1) 5/240 (2.1) 2.30 (0.80–6.62)  1.96 (0.67–5.75)  
   HF and EF ≥40% 31/1427 (2.2) 44/1405 (3.1) 27/1418 (1.9) 1.14 (0.68–1.91)  1.68 (1.04–2.71)  
   HF and EF unknown 7/300 (2.3) 2/310 (0.6) 4/321 (1.2) 1.66 (0.48–5.68)  0.67 (0.11–4.03)  
  Symptomatic bleeding into a 
critical organ
    0.57  0.92
   HF and EF <40% 3/236 (1.3) 2/245 (0.8) 2/240 (0.8) 1.66 (0.28–9.96)  0.98 (0.14–6.95)  
   HF and EF ≥40% 10/1427 (0.7) 13/1405 (0.9) 9/1418 (0.6) 1.12 (0.46–2.77)  1.45 (0.62–3.40)  
   HF and EF unknown 4/300 (1.3) 1/310 (0.3) 1/321 (0.3) 3.78 (0.42–33.9)  -  
  Intracranial bleeding     0.89  0.99
   HF and EF <40% 2/236 (0.8) 0/245 (0) 1/240 (0.4) 2.23 (0.20–24.7)  -  
   HF and EF ≥40% 5/1427 (0.4) 5/1405 (0.4) 4/1418 (0.3) 1.23 (0.33–4.60)  1.24 (0.33–4.62)  
   HF and EF unknown 2/300 (0.7) 1/310 (0.3) 1/321 (0.3) 1.95 (0.18–21.5)  -  
Net clinical benefit outcome
  Cardiovascular death, stroke, 
myocardial infarction, fatal 
bleeding, or symptomatic 
bleeding into a critical organ
    0.48  0.35
   HF and EF <40% 26/236 (11.0) 33/245 (13.5) 31/240 (12.9) 0.83 (0.49–1.41)  1.07 (0.66–1.75)  
   HF and EF ≥40% 75/1427 (5.3) 83/1405 (5.9) 104/1418 (7.3) 0.70 (0.52–0.95)  0.80 (0.60–1.07)  
   HF and EF unknown 15/300 (5.0) 18/310 (5.8) 30/321 (9.3) 0.53 (0.28–0.98)  0.64 (0.35–1.15)  
Percent (%) is the proportion of patients with an outcome. HRs (95% CI) are from the stratified Cox proportional hazards regression models fit in the respective 
subgroup. EF indicates left ventricular ejection fraction; HF, heart failure; and HR, hazard ratio.
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in the effects of rivaroxaban and aspirin compared with 
aspirin alone in the subgroups defined by baseline EF.
In patients with chronic atherosclerotic disease, a di-
agnosis of HF increases the risk of MACE, hospital re-
admission, and mortality compared with those without 
HF, regardless of whether HF is related to preserved or 
reduced EF.5 Recognition of the increased risk of cardio-
vascular events in patients with HF informed the design 
of clinical trials of antithrombotic therapies in HF. Most 
of these trials focused on patients with HFrEF or early 
after MI6–9 and did not show a benefit of antithrom-
botic therapy with routine use.6–9 Vitamin K antagonists 
given alone or in combination with aspirin reduced 
stroke compared with aspirin alone, but the increase 
in bleeding negated the stroke benefit. Thus, current 
guidelines recommend routine antithrombotic therapy 
only in patients with HF at higher thromboembolic risk, 
such as those with left ventricular thrombus or atrial fi-
brillation.10,11 In COMPASS, we did not collect informa-
tion on atrial fibrillation at randomization, although pa-
tients requiring full anticoagulation were excluded, and 
only 1.4% developed atrial fibrillation during the mean 
23 months of follow-up. Most COMPASS patients with 
a history of HF had EF ≥40%, a patient population that 
has high risk but relatively few treatment options to 
improve cardiovascular outcomes.12 In this context, the 
results with the combination of rivaroxaban and aspirin 
may represent a worthwhile treatment option.
Table 4. Comparison of COMMANDER HF and COMPASS Patients With HF at Baseline and EF<40%
Population
COMPASS (Chronic CAD, History of HF With EF <40%)
COMMANDER HF* 
(CAD, EF <40%, Recent 
HF Hospitalization)
Riva+ASA (N=236) ASA (N=240) HR (95% CI) HR (95% CI)† (N=5022)
Composite end point (all-cause 
death, MI, stroke)
30 (13%) 34 (14%) 0.87 (0.53–1.43) 0.94 (0.84–1.05)
CV death 16 (7%) 19 (8%) 0.84 (0.43–1.64) 0.95 (0.84–1.08)
Stroke 5 (2%) 7 (3%) 0.74 (0.23–2.35) 0.66 (0.47–0.95)
MI 6 (3%) 10 (4%) 0.56 (0.2–1.55) 0.83 (0.63–1.08)
All-cause death 23 (10%) 24 (10%) 0.96 (0.54–1.71) 0.98 (0.87–1.10)
Hospitalization for heart failure 16 (6.8) 20 (8.3) 0.77 (0.40–1.48) 0.98 (0.89–1.09)
ASA indicates aspirin; CAD, coronary artery disease; CV, cardiovascular; EF, left ventricular ejection fraction; HF, heart failure; HR, hazard ratio; 
MI, myocardial infarction; and Riva, rivaroxaban.
*Ninety-three percent of COMMANDER HF participants were taking ASA. 
†HR for rivaroxaban 2.5 mg BID compared with placebo.
Figure 2. Clinical trial events in patients with HF and CAD or PAD treated with rivaroxaban with or without aspirin.  
Comparison of total event rates for primary end point, their components, and noncardiovascular death in COMMANDER HF (A Study to Assess the Effectiveness 
and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction, or Stroke in Participants with Heart Failure and Coronary Artery Disease Following 
an Episode of Decompensated Heart Failure) and in patients in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) with HF, 
by left ventricular ejection fraction category. Multiple events could occur in a single patient. ACS indicates acute coronary syndrome; ASA, aspirin; ATLAS ACS-2, 
Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome; CAD, coronary artery disease; CV, 
cardiovascular; EF, ejection fraction; HF, heart failure; PAD, peripheral artery disease; and Riva, rivaroxaban.
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The COMPASS results described in the present report 
add incremental information to those of 2 other large tri-
als that also tested the combination of low-dose rivarox-
aban and aspirin in patients with HF, but in very different 
patient populations. The COMMANDER HF trial random-
ized patients with HFrEF (EF <40%) with recent hospi-
talization for acute HF decompensation to rivaroxaban 
versus placebo alone, with 93% on aspirin. The rate of 
combined all-cause mortality, MI, and stroke was 26.2% 
over the median 21-month follow-up, which is substan-
tially higher than the 12.9% rate of this same outcome 
in COMPASS patients with EF ≤40% over a median 
23-month follow-up. The most important reason for this 
difference was the much higher cardiovascular mortality 
rate in COMMANDER HF compared with COMPASS HF 
patients, likely driven by the acute or recently decom-
pensated HF in COMMANDER HF compared with the 
chronic, stable HF cohort in COMPASS (Figure 2; Table 4). 
Death of patients with severe HF is commonly attribut-
able to arrhythmia or pump failure, which may not be 
substantially impacted by rivaroxaban2 (Figure 2). Thus, 
rivaroxaban administration in COMMANDER HF did not 
significantly reduce the relative risk of the combined end 
point of death, MI, or stroke, which appears directionally 
similar to the COMPASS results in patients with EF <40% 
(Figure 2; Table 4). However, stroke and MI were reduced 
by a relative 34% and 17%, respectively, in COMMAND-
ER HF, which is similar to the results in the COMPASS HF 
cohort with EF <40% (Figure 2; Table 4).13
Combination rivaroxaban with aspirin was also test-
ed in the ATLAS ACS 2 trial (Anti-Xa Therapy to Lower 
Cardiovascular Events in Addition to Standard Therapy 
in Subjects With Acute Coronary Syndrome), in which 
patients were enrolled early after acute coronary syn-
drome, treated with either dual-antiplatelet therapy 
(93%) or aspirin (7%), and randomized to rivaroxaban 
2.5 mg BID and 5 mg BID.14 ATLAS ACS 2 demonstrat-
ed significant reductions in MACE and all-cause mortal-
ity with low-dose rivaroxaban 2.5 mg BID, as well as 
an expected increase in major bleeding. In the subset 
of patients with HF at randomization (1694 [10.9%]), 
these MACE benefits were amplified, with a 41% rela-
tive risk reduction compared with placebo (16.8% to 
10.1% for patients with and without HF; HR, 0.59; 
95% CI, 0.42–0.81; P=0.002 for interaction). In ad-
dition, patients with HF had a 57% relative mortality 
reduction, from 9.3% to 4.1% the rivaroxaban 2.5 mg 
BID compared with placebo.15
Although the patient populations in COMMANDER 
HF, ATLAS ACS-2, and COMPASS were somewhat dif-
ferent, when taken together, the results suggest that 
rivaroxaban 2.5 mg BID provides antithrombotic ben-
efits in patients with chronic HF. However, rivaroxaban 
appears to preferentially benefit those patients with 
mild to moderate HF who do not have recent decom-
pensated HF or advanced HFrEF.
Study Limitations
These data are based on a subgroup of patients with 
HF, and information on EF was incomplete. Thus, any 
conclusions should be viewed with appropriate caution.
Conclusions
In patients with chronic CAD or PAD, rivaroxaban 2.5 mg 
BID plus aspirin as compared to aspirin alone produces 
similar relative risk reductions but larger absolute risk 
benefits in patients with mild to moderate HF who do 
not have recent decompensated HF or advanced HFrEF.
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